Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.
Company profile
Ticker
PTGX
Exchange
Website
CEO
Dinesh V. Patel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Protagonist Inc, Protagonist Therapeutics Inc
SEC CIK
Corporate docs
Subsidiaries
Protagonist Pty Limited ...
IRS number
980505495
PTGX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
6 Jan 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8 Nov 22
EFFECT
Notice of effectiveness
17 Aug 22
CORRESP
Correspondence with SEC
12 Aug 22
UPLOAD
Letter from SEC
9 Aug 22
S-3
Shelf registration
5 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
2 Jun 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 153.04 mm | 153.04 mm | 153.04 mm | 153.04 mm | 153.04 mm | 153.04 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 10.77 mm | 10.99 mm | 8.40 mm | 8.62 mm |
| Cash used (since last report) | n/a | n/a | 45.46 mm | 46.40 mm | 35.47 mm | 36.39 mm |
| Cash remaining | n/a | n/a | 107.58 mm | 106.64 mm | 117.57 mm | 116.65 mm |
| Runway (months of cash) | n/a | n/a | 10.0 | 9.7 | 14.0 | 13.5 |
Institutional ownership, Q3 2022
96.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 127 |
| Opened positions | 28 |
| Closed positions | 36 |
| Increased positions | 39 |
| Reduced positions | 39 |
| 13F shares | Current |
|---|---|
| Total value | 525.15 mm |
| Total shares | 47.35 mm |
| Total puts | 101.60 k |
| Total calls | 746.80 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 4.89 mm | $167.31 mm |
| RTW Investments | 4.18 mm | $35.21 mm |
| Farallon Capital Management | 3.65 mm | $30.79 mm |
| BLK Blackrock | 3.46 mm | $29.19 mm |
| Vanguard | 2.94 mm | $24.81 mm |
| FMR | 2.81 mm | $23.68 mm |
| Point72 Asset Management | 2.54 mm | $21.40 mm |
| JNJ Johnson & Johnson | 2.45 mm | $20.65 mm |
| Bain Capital Life Sciences Investors | 2.26 mm | $19.06 mm |
| MS Morgan Stanley | 2.23 mm | $18.78 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Jan 23 | Dinesh V PH D Patel | Stock Option Common Stock | Grant | Acquire A | No | No | 12.17 | 600,000 | 7.30 mm | 600,000 |
| 16 Jan 23 | Molina Arturo MD | Common Stock | Grant | Acquire A | No | No | 0 | 3,125 | 0.00 | 24,375 |
| 16 Jan 23 | Molina Arturo MD | Stock Option Common Stock | Grant | Acquire A | No | No | 12.17 | 18,750 | 228.19 k | 18,750 |
| 16 Jan 23 | Asif Ali | Common Stock | Grant | Acquire A | No | No | 0 | 10,625 | 0.00 | 24,375 |
| 16 Jan 23 | Asif Ali | Stock Option Common Stock | Grant | Acquire A | No | No | 12.17 | 63,750 | 775.84 k | 63,750 |
| 16 Jan 23 | Suneel Gupta | Common Stock | Grant | Acquire A | No | No | 0 | 20,625 | 0.00 | 138,187 |
| 16 Jan 23 | Suneel Gupta | Stock Option Common Stock | Grant | Acquire A | No | No | 12.17 | 123,750 | 1.51 mm | 123,750 |
| 16 Jan 23 | Harold E Selick | Stock Option Common Stock | Grant | Acquire A | No | No | 12.17 | 30,000 | 365.10 k | 30,000 |
| 28 Dec 22 | Dinesh V PH D Patel | Common Stock | Gift | Dispose G | No | No | 0 | 3,116 | 0.00 | 598,096 |
| 4 May 22 | Dinesh V PH D Patel | Common Stock | Gift | Dispose G | No | No | 0 | 3,000 | 0.00 | 581,048 |
Press releases
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
21 Dec 22
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
1 Dec 22
Protagonist Therapeutics Reports Granting of Inducement Award
16 Nov 22
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8 Nov 22